Strumento inattivo

Altre lingue Spark Therapeutics Inc Nasdaq

Azioni

Prezzo di chiusura Nasdaq Altri mercati azionari
-	-

2023	Spark Therapeutics rescinde l'accordo di collaborazione per il progetto di epilessia CG01 con CombiGene AB (publ)	CI
2023	Spark Therapeutics, Inc. Entra in una collaborazione strategica con Neurochase Limited per l'uso della tecnologia di somministrazione proprietaria per i disturbi del SNC	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB	14/10/23
One of Nature’s journals publishes article about CombiGene’s epilepsy project	11/04/23
Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies Updates Cash Runway Guidance	30/01/23
Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders	30/01/23
Spark Therapeutics, Inc. Enters into Strategic Collaboration with Neurochase Limited for Use of Proprietary Delivery Technology for CNS Disorders	27/01/23
Roche: Gentherapie SPK-8011 von Tochter Spark erweist sich als dauerhaft wirksam	12/12/22
Spark Therapeutics, Inc. Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A	12/12/22
Watch CEO Jan Nilsson’s presentation at Aktiedagen Göteborg	17/05/22
CombiGene presents at Aktiedagen Göteborg on Monday 16 May	10/05/22
BioStock: CombiGene strives for a broader pipeline	21/04/22
Spark Therapeutics, Inc. Announces Executive Changes, Effective April 1, 2022	23/02/22
CombiGene launches new website	21/02/22
Year-end report January-December 2021 CombiGene AB (Publ)	17/02/22
BioStock: CombiGene's CEO gives business development update	11/02/22
CombiGene’s and Neurochase’s preclinical study provides valuable information for the upcoming long-term studies in toxicology and biodistribution	08/02/22
GMP production of CG01 made available for preclinical studies planned to enable First in Human study	17/01/22
Spark Therapeutics to Invest $575M in New 500k Square Foot State-of-the-Art Gene Therapy Innovation Center on Drexel's University City Campus	20/12/21
BioStock: CombiGene's CEO about the path to the first clinical trial	20/12/21
CombiGene and Spark Therapeutics plan to expand the clinical development program to include the U.S. as well as Europe	16/12/21
Combigene and Spark Therapeutics Plan to Expand the Clinical Development Program to Include the U.S. as Well as Europe	16/12/21

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Spark Therapeutics Inc Nasdaq

Azioni

Altre lingue

Filtri